Abstract | Over the past several years, the field of cancer research has directed increased interest towards subsets of obesity-associated tumours, which include mammary, renal, oesophageal, gastrointestinal and reproductive cancers in both men and women. The increased risk of breast cancer that is associated with obesity has been widely reported; this has drawn much attention and as such, warrants investigation of the key mechanisms that link the obese state with cancer aetiology. For instance, the obese setting provides a unique adipose tissue microenvironment with concomitant systemic endocrine alterations that favour both tumour initiation and progression. Major metabolic differences exist within tumours that distinguish them from nontransformed healthy tissues. Importantly, considerable metabolic differences are induced by tumour cells in the stromal vascular fraction that surrounds them. The precise mechanisms that underlie the association of obesity with cancer and the accompanying metabolic changes that occur in the surrounding microenvironment remain elusive. Nonetheless, specific therapeutic agents designed for patients with obesity who develop tumours are clearly needed. This Review discusses recent advances in understanding the contributions of obesity to cancer and their implications for tumour treatment.
Introduction
In the context of metabolism, the basic principles of conservation of energy dictate that excess energy intake and decreased physical activity result in an increased accumulation of adipose tissue, leading to obesity. Excess adipose tissue accrual is associated with dysfunction of this tissue, which can predispose indivi duals to develop type 2 diabetes mellitus (T2DM) and cardiovascular disease. 1 Additionally, indivi duals who are overweight (BMI 25.0-29.9 kg/m 2 ) or who have obesity (BMI ≥30 kg/m 2 ) are at increased risk of developing several types of cancer. Growing evidence from both clinical and preclinical studies indicates that increased adiposity is associated with increases in cancer incidence, morbidity and mortality. 2, 3 However, despite strong epidemiological evidence linking obesity to increased cancer risk and mortality, 4, 5 mechanis tic insights explaining these data are notably lacking. Results from preclinical studies suggest that components of chronic inflammation (which is often associated with obesity), as well as the unique nature of cancer stem cells (CSCs) derived from adipose tissue in indivi duals with obesity, might contribute to the increased cancer risk of such patients. [6] [7] [8] Moreover, prediagnosis BMI is an important indicator of survival in patients who develop colorectal cancer, 9 and poorer prognosis and higher recurrence rates of cancer after radiotherapy or chemo therapy are more frequently observed in patients with obesity than in lean ones. 10, 11 Together, these observa tions highlight the need to focus research on the contri butions of obesity to cancer incidence and outcomes. Understanding the key pathological features of dys functional adipose tissue might, therefore, offer impor tant mechanistic insights into the relationship between obesity and cancer. 3 Three main factors are considered to connect obesity and cancer: the insulin-IGF1 axis, sex hormones, and the adipocytederived cytokines (termed adipokines). Each of these three factors is intimately linked to endo crine and paracrine dysregulation of adipose tissue in obesity. 3 For example, local metabolic alterations in adipose tissue in individuals with obesity result in multiple systemic metabolic alterations, such as insulin resistance, hyperglycaemia, dyslipi daemia and chronic inflammation. 12, 13 Tumours invade stromal compart ments that are rich in adipose tissue, and adipo cytes function as endocrine cells to critically shape the tumour microenvironment and contribute to tumour development and progression. 3 These changes con tribute to the increased cancer risk and poor outcomes in individuals with obesity. In this Review, we will discuss the metabolic symbiosis between adipocytes and tumour cells with respect to subtypes of lipid metabolites, hyperglycaemic memory effects and adipo cyte progenitor cells. We will also consider how these factors are associated with metabolic abnormalities in the adipose tissue of individuals with obesity, and ways in which they could influence obesityrelated cancer risk and mortality.
The link between obesity and cancer
Adipose tissue and the tumour microenvironment The survival of cancer cells is critically dependent on their interactions with neighbouring nonmalignant cells of the tumour stroma. These cells include fibro blasts, endothelial cells and pericytes, all of which are embedded in a unique extracellular matrix. 14 The con tributions of the tumour stroma to cancer cell survival have been widely studied. A primary focus of investi gations has been on cancerassociated fibroblasts and tumourassociated macrophages, both of which are well established tumourpromoting cell types. 15, 16 The adipocytes surrounding tumours are another major com ponent of the tumour stroma. Moreover, adipose tissue within the tumour microenvironment actively contrib utes to tumour growth and metastasis by functioning as an endocrine organ, through secretion of signalling mol ecules (such as adipokines, proinflammatory cytokines, proangiogenic factors and extracellular matrix constitu ents) and acting as an energy reservoir for embedded cancer cells. [17] [18] [19] Thus, the importance of adipose tissue as an integral contributor to cancer progression and r ecurrence is increasingly appreciated. 20 Hypertrophic expansion of adipose tissue in the context of obesity shares many features with solid tumour growth. For example, tumour hypoxia is a hall mark of cancer that is associated with poor patient out comes and resistance to chemotherapy. 21, 22 The rapid cellular proliferation and expansion of adipose tissue also induces hypoxia, which triggers compensatory angio genesis, so that limitations in nutrient and oxygen supply can be overcome. 23 Similar to that seen in tumour growth, the hypoxia in adipose tissue that occurs in the context of obesity induces expression of the transcription factor HIF1α, which upregulates a profibrotic pathway involving extracellular matrix proteins (such as colla gens, matrix metallo proteinases and tissue inhibitors of metalloproteinases) and proinflammatory cytokines (such as IL6, tumour necrosis factor [TNF] and CC motif chemokine 2 [CCL2, also known as monocyte chemo tactic protein 1]). [24] [25] [26] The micro environment within local adipose deposits clearly provides a tumour permissive niche for transformed, infiltrating cells. Importantly, fibrotic and proinflammatory cytokines that are characteristic of adipose tissue in individuals with obesity, such as endotrophin (a Cterminal cleavage
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Cancer-associated adipocytes
Adipose tissue comprises a heterogeneous cell popu lation, which mostly consists of adipocytes but also contains various other stromal cells, including endo thelial cells, pericytes, macrophages and adipocyte pro genitor cells. Both adipocytes and the stromal vascu lar cells in adipose tissue contribute to tumour develop ment and progression. 29 In a subset of tumours, such as breast, prostate, ovarian, gastric, renal and colon can cers, growth and/or metastasis predominantly occur as a result of the adipocyterich micro environments in which these tumours are found, and reflect a role for adipo cytes in tumour maintenance and progression. 17, 20 For many of these cancers, the degree of adipose tis sue invasion is a reflection of the aggressiveness of the tumour, and extensive invasion is indicative of poor prognosis. 30, 31 Emergence of rapidly proliferat ing stro mal cells is also a feature of the hypertrophic and hyper plastic expansion of adipose tissue in obesity. As such, adipocyte progenitors in stromal vascular fractions rapidly proliferate and differ entiate into mature adipo cytes. 32 Given this simi larity, it is plausible that multi potent adipocyte progenitors in the stromal vascu lar fraction might contribute to cancer development and progression. Several reports show that adipocyte pro genitors in adipose tissues from individuals with obesity contribute to tumour progression through increasing the number of endothelial precursors, pericytes and adipocytes, thereby resulting in angiogenesis and cancer cell pr oliferation in vivo. 33, 34 Cancerassociated adipocytes (CAAs) undergo con siderable morphological and functional alterations dur ing cancer progression. In the presence of cancer cells, especial ly at the tumour invasive front, CAAs undergo delipidation and acquire a fibroblastlike phenotype. This phenotypic change is accompanied by loss of expression of adipocyte terminal differenti ation markers, such as adiponectin, leptin and fatty acid binding protein, intestinal (FABP2) and by increased secretion of proinflammatory cytokines such as IL6 and PAI1. 35, 36 In vitro experiments, in which no direct contact is permitted between differentiated adipocytes and tumour cells, demonstrate that secreted paracrine signals from cancer cells can induce lipolysis in adipo cytes, causing them to release free fatty acids. 36 CAA delipidation and the accompanying increase in secre tion of inflammatory cytokines and proteases creates an environ ment that encourages a shift in tumour cell pheno type towards increased invasiveness and a ggression (Figure 1 ). 36 The adipocyterich tissue surrounding tumour cells offers an easily accessible reservoir of lipids, and the pheno typic transition of CAAs is likely to reflect the high energy requirements of cancer cells. Cancer cells can use free fatty acids as a fuel source, particularly if they metasta size to the abdominal cavity where there is easy access to adipocytes. 17 Cancer cells also reprogram adipocytes into CAAs to support tumour growth and survival. Nevertheless, the mechanisms that dictate the heterotypic crosstalk between cancer cells and adipocytes need to be further studied.
The source of the increased population of fibroblast like cells among CAAs remains unclear. Cancer cells might induce nonmalignant stromal cells, such as fibro blasts and macrophages, to become cancerassociated fibroblasts and tumourassociated macrophages. 14, 37 The question of whether these cells dedifferentiate from mature adipocytes, are newly recruited cells of mesenchymal origin, or are simply delipidated mature adipocytes that still express most of the characteristic adipocyte markers, remains unanswered.
Cancer stem cells Stromal cell populations that have tumorigenic potential and drive tumour growth are known as CSCs. 38 These cells are commonly isolated from tumours using a combi nation of positive and negative selection markers; for example, breast cancer stem cells are represented by the CD44 + CD22 low subset within a given tumour. 39 Many other solid tumours contain CSCs, which can drive metastasis, cancer recurrence and drug resistance; 40 CSCs are, therefore, a key target of anticancer therapeu tic agents. 41 Various types of CSCs will only proliferate rapidly in a specific permissive tumour microenviron ment, indicating a crucial role of environmental stimuli to support tumour growth and survival. 38 Various cytokines released from adipose tissue in obese states stimulate CSC growth and survival. High levels of proinflammatory cytokines, such as IL6 and IL8, stimulate CSCs in breast cancer models. 42, 43 Furthermore, TGFβ confers stemcelllike traits to cancer cells as well as inducing epithelial-mesenchymal transition (EMT), 44, 45 and leptin has a key role in stimu lation and maintenance of certain populations of CSCs in breast cancer models, as discussed above. 46, 47 Our group also reported that endotrophin potentiates TGFβdependent EMT, which results in high levels of metastasis and resistance to chemotherapy. 19, 48 Clinically, individuals with obesity display more resistance to chemo therapy or radiotherapy than do lean individuals, which is in part due to the increased number of CSCs present in the adipose tissue of i ndividuals with obesity.
Obesity-related inflammation
Chronic inflammation, which is exemplified by elevated circulating levels of IL6 and TNF, is associated with obesity. 49 Additionally, an accumulating body of clini cal data suggests that individuals with obesity are at an elevated risk of developing several types of cancer. Many preclinical studies have, therefore, focused attention on inflammation as a possible mechanism linking obesity with increased tumour burden. 8, 50, 51 Liver cancer Exposure of male C57BL/6J mice to a highfat diet (HFD) resulted in increased incidence of spon taneous hepato cellular carcinoma (HCC), although this effect was not observed in other inbred mouse strains. 52 Interest ingly, notable differences were observed between the weights of the different inbred strains of mice fed a HFD: male C57BL/6J mice fed a HFD were on average 60-70% heavier than inbred male A/J mice receiving the same diet, suggesting that genetic background contri butes to both dietinduced obesity and development of HCC.
The link between obesity and cancer was also explored using another model of HCC, in which diethyl nitrosamine was administered by injection 14 days after birth, which resulted in hepatic adenoma formation by 8 months of age. In these experiments, both obese mice fed a HFD and leptindeficient Lep ob/ob mice (which are genetically predisposed to obesity) demonstrated an increased tumour burden compared with lean mice after challenge with diethylnitrosamine. 8 Female C57BL/6 mice, which show attenuated inflammation in res ponse to a HFD, as well as male IL6knockout and TNF knockout mice, were protected from increased HCC incidence under conditions of HFDinduced obesity, 8 suggesting that elevated circulating levels of IL6 and TNF in the obese animals were responsible for this d ifference in tumour initiation. 8 Another research group subsequently showed that acyclic retinoids can inhibit diethylnitrosamineinduced hepatic neoplasia in obese mice. 53 Treatment with these agents decreased levels of Stat3 protein, which is a down stream mediator of IL6 signalling. Total serum levels of both IL6 and TNF were decreased in the acyclic retinoidtreated mice, suggesting that these compounds prevent HCC tumourigenesis in HFDfed mice through inhibition of the IL6-Stat3 axis. Colon cancer Individuals with obesity are at an increased risk of developing colon cancer, 54 and these findings have been readily recapitulated in rodent models. Specifically, Zucker obese rats, KKAy mice and HFDfed mice all show an increased incidence of colon cancer fol lowing treatment with azoxymethane as compared to controls. 55, 56 A key finding that implicated inflammation in colon cancer initiation was that Lep ob/ob mice fed a beanbased diet had a considerably lower tumour burden follow ing azoxymethane treatment than did Lep ob/ob mice fed a standard diet. 57 The researchers attributed this observation to the fact that consumption of the bean diet resulted in considerably lower serum levels of IL6. Treatment of leptinreceptordeficient Lepr db/db mice with the ch olesterollowering drug pitavastatin resulted in decreased levels of circulating inflamma tory cytokines, as well as reduced tumour initiation. 58 Additionally, administration of angiotensin converting enzyme inhibitors or angiotensinreceptor blockers reduced chronic inflammation in the Lepr db/db mouse, thereby attenuating tumour initi ation. 59 Although all of these studies have reached similar conclu sions, the field still lacks the neces sary preclinical models to demon strate direct causality and, there fore, these findings remain correlative at best. Cell typespecific elimination of the IL6 receptor in these models might, however, provide important insights into the relationship between obesity, inflammation and tumourigenesis.
Some direct evidence that inflammatory signalling has a role in colitisassociated cancer does exist. Results in a dextransodiumsulphate-azoxymethane model of intestinal inflammation in global IL6knockout mice, or mice with specific ablation of Stat3 from the gut, showed that the IL6-Stat3 inflammatory axis contrib uted to tumour formation, and loss of IL6 signalling resulted in significantly attenuated tumour develop ment and progression. 60 However, these studies did not provide evidence linking HFDinduced inflammation with increased tumour risk.
Emerging evidence suggests that TNF is a key medi ator of both obesityinduced inflammation and colon cancer development. TNF is highly elevated in the colons of C57/BL6 mice fed a HFD. 61 Treatment with infliximab, a TNFneutralizing monoclonal anti body, decreased growth of colon cancer xenografts and decreased tumour incidence in azoxymethanetreated Lep ob/ob mice. 51 These data provide compelling evidence that local inflammation, primarily mediated by TNF, has a key role in tumour initiation in obese rodents.
Adipokines
Leptin Leptin is a 16 kD hormone produced by adipocytes, and is known primarily for its role in the mammalian central nervous system, where it regulates food intake. Leptin receptors are expressed in almost every tissue and have a dynamic role in many organ systems, including the regulation of cancer growth. Leptin levels rise dramati cally during states of obesity, and as a result, this adipo kine is thought to have a pivotal role at the interface of obesity and cancer development.
Role in colon cancer
A case-control study conducted in the USA demon strated that men with colorectal adenomas had elevated circulating leptin levels. 62 However, the findings of this study have since been challenged. Other researchers demonstrated that leptin levels were not significantly correlated with increased colorectal cancer burden when factors such as BMI and waist circumference were taken into consideration. 63 Regardless of the contrary out comes reported, studies such as these have prompted investigations into the role of leptin in the development of colorectal cancer in both humanderived cell lines and in mouse models.
In the human colorectal cancer cell line HCT116, leptin activates the PI3K-AKT pathway, resulting in increased cancer cell proliferation. 64 This growth stimulatory effect of leptin was mitigated by treat ment with the PI3K inhibitor LY294002. Notably, other groups have argued that the Jak2-STAT3activating capacity of leptin is responsible for stimulating colon cancer cell proliferation. 65 However, these pathways are clearly not mutually exclusive, and these findings could simply imply that therapies targeting multiple pathways might be needed in certain patient popula tions. 64, 66 Lep ob/ob mice are significantly less sensitive to azoxymethaneinduced polyp formation than are wild type controls, 66 suggesting a role for leptin in stimulating initiation of colon cancer. Furthermore, a comparison of wildtype and Lep ob/ob mice fed a HFD (a challenge that is strongly associated with increased polyp formation) showed that Lep ob/ob mice were strongly protected from polyp f ormation compared with wildtype mice. 66 Role in ovarian cancer A study of epithelial ovarian cancers in Middle Eastern women revealed that up to 60% of tumours showed overexpression of the leptin receptor, and that this upregulation correlated with reduced progressionfree survival. 67 These findings stimulated further research to identify a mechanism whereby leptin might influence the growth of ovarian cancer cells. Investigations in the OVCAR3 ovarian cancer cell line showed that leptin signalling inhibited apoptosis and stimulated cell divi sion, via inhibition of p21 and increased expression of cyclin D1 and myeloid cell leukaemia sequence 1. 68, 69 Interestingly, exposure to bisphenol A, a common mol ecule found in many plastics, increased leptin recep tor expression and inhibited caspase3 expression and activity in ovarian cancer cell lines. 51, 70 Moreover, the inhibition of caspase3 activity was augmented by expo sure to estrogen. 71 Together, these observations demon strate a direct role for leptin in the growth and survival of ovarian cancer cells, but further in vivo studies are clearly needed to gain a thorough understanding of the relevance of these findings to the clinical setting.
Role in breast cancer
A metaanalysis showed that women with breast cancer frequently exhibit significantly elevated circulating levels of leptin, which suggests a role for this adipokine in dis ease progression. 72 Furthermore, patients with breast cancer who had increased levels of leptin receptor mRNA transcripts in their tumours, concomitant with elevated serum leptin levels, had a poorer prognosis than did their counterparts without these factors. 73 Studies in breast cancer cell lines showed that leptin induced growth of breast tumour cells through activa tion of the JAK-STAT and PI3K signalling pathways. 74 Leptin also potently activated the migration and motil ity of breast cancer cells. 75 Moreover, leptin signalling maintained CSClike properties in triplenegative breast cancer cells (that is, lacking expression of the estrogen receptor, progesterone receptor and HER2), which enabled CSCs with selfrenewal capacity to mediate tumour recurrence and metastasis. 7 Contributions of leptin to mammary tumour development have also been assessed in a rodent model. In the MMTVPyMT mammary tumourprone model, hypothalamus specific restoration of functional leptin receptors in female Lepr db/db mice normalized their ductal develop ment, and also ameliorated the obesity phenotype of these animals. 76 Peripheral leptinreceptordeficiency in these MMTVPyMT mice attenuated tumour growth and metastasis, indicating that these characteristics are indepen dent of the tumour and reflect the metabolic state of the host. The leptinreceptordeficient tumour cells also had higher mitochondrial respiration capacity and attenuated activation of ERK and Stat3. 76 Overall, these observations demonstrate that leptinreceptor signalling has a crucial role in mammary cancer pro gression, and that inhibition of this pathway could hold substantial therapeutic benefit.
Adiponectin
Adiponectin is primarily known for its role in insulin sensitization of tissues such as muscle and liver. Long thought to act through an AMP kinase (AMPK) dependent signalling pathway, emerging evidence now suggests that adiponectin modulates the activity of a ceramidase, which leads to decreased intracellular levels of ceramides, improved insulin sensitivity and inhibition of apoptosis. 77 In the past 20 years, substan tial efforts have been directed toward identifying the functions of adiponectin in various tissues, including its effects on tumour growth.
Role in HCC
In experiments using a cholinedeficient laminoacid defined diet, which predisposes mice to nonalcoholic steatohepatitis, adiponectinknockout mice bore signifi cantly more tumours in their livers after 24 weeks than did control mice. These findings demonstrated that loss of adiponectin renders the liver more susceptible to hepatic adenoma formation. 78 Adiponectin also increased caspase3 activation and apoptosis in HCC cell lines, via inhibition of serine-threonineprotein kinase mTOR (mTOR), in a cJNK dependent manner. 79 These tumourinhibiting effects of adponectin were corrobor ated by in vivo observations showing that overexpression of adiponectin resulted in inhibi tion of tumour growth and metastasis in nude mice. 80 Interestingly, these experi ments also found decreased macrophage and hepatic stellate cell infiltration into the tumour grafts, as well as decreased angiogenesis, sug gest ing that these functions are the primary mechanisms by which adiponectin exerts its anticancer effects in the context of HCC.
In states of obesity, adiponectin levels decrease and leptin levels rise. In a study assessing this dynamic relation ship between the adipokines and their effects on tumour progression, adiponectin inhibited the leptin induced proliferation of HCC tumour cells via decreased activation of Stat3. 81 These findings were confirmed in a xenograft model with nude mice, in which adiponectin treatment was associated with a significantly reduced leptininduced tumour burden.
Role in colon cancer
A prospective study has demonstrated that low levels of plasma adiponectin are correlated with an increased risk of colon cancer; 82 however, the mechanisms through which adiponectin protects against colon cancer for mation remain unknown. Adiponectin receptors are expressed on both normal and malignant intestinal epi thelial cells, suggesting that adiponectin could exert its antitumour effects in either a cell autonomous or non autonomous fashion. 83 This hypothesis has been tested by several groups, who have determined that adipo nectin activates AMPK signalling, and the consequent suppression of mTOR and S6 kinase phosphorylation results in inhibition of cell proliferation. 84, 85 Several in vivo studies have demonstrated that adiponectin deficiency promotes intestinal carcinogenesis in both APC Min mice (which spontaneously develop intesti nal tumours) and wildtype mice treated with azoxy methane. 86 By contrast, other groups showed that adi ponectin deficiency alone did not promote polyp formation in mice fed standard chow, but did signifi cantly increase polyp formation in mice subjected to azoxymethane challenge and fed a HFD. 87 These studies clearly demonstrate a role for adiponectin as a repressor of intestinal tumour initiation.
Role in breast cancer
Strong evidence supports an epidemiological relation ship between obesity, low levels of adiponectin and an increased incidence of breast cancer; 88 however, pre clinical studies from our own and other groups suggest that a nuanced assessment of the contribution of adipo nectin to this relationship needs to be applied if we go beyond the use of this hormone as an obesity marker. Using the MMTVPyMT mouse model of breast cancer, we and others have demonstrated that delayed tumour development occurs in adiponectinnull mice, 89, 90 and that the proangiogenic effects of adiponectin also enhance tumour neovascularization. 70 These findings are consistent with observations of enhanced accumu lation of sphingosine1phosphate, which is a potent pro angiogenic stimulus, in the presence of elevated ad iponectin levels.
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Metabolic symbiosis-cancer and obesity
Warburg and reverse Warburg effects
The Warburg effect is the most widely appreciated metabolic phenotype in cancer cells. This term refers to a metabolic shift in ATP generation from oxidative phosphorylation to glycolysis, which occurs even under aerobic conditions. 91 Emerging insights also emphasize the importance of metabolites from tumour stromal cells, with a special focus on those secreted by cancer associated fibroblasts, which are utilized by cancer cells for growth and metastasis. 15 This phenomenon is referred to as the reverse Warburg effect, which posits that aerobic glycolysis occurs in stromal cells rather than cancer cells, and provides lactate and pyruvate to cancer cells through a paracrine exchange of these nutrients. 92 The transferred nutrients are used by cancer cells to gener ate energy by mitochondrial oxidative metabolism. 93 Similarly, increased lipolytic activity in stromal adipocytes provides free fatty acids to tumour cells, which are then utilized as an energy source to facilitate βoxidation in the cancer cell mitochondria. 17 Collectively, cancer cells are metabolically very flexible and actively direct the metabolism of tumour stromal cells, such as fibroblasts and adipocytes, to take advan tage of the unique tumour microenvironment. In other words, catabolic pathways in these tumour stromal cells fuel anabolic tumour growth by transferring high energy metabolites such as lactate, ketones, glutamine and fatty acids to cancer cells.
Hyperglycaemia
The results of clinical studies and metaanalyses indicate that an important association exists between diabetes mellitus and a subset of cancers, including liver, pan creas, endometrium, colorectal, breast and renal cancers; however, little is known about the molecular mechanisms underlying these connections. 94 Hyperglycaemia is a hallmark of both type 1 diabetes mellitus and T2DM. Furthermore, hyperglycaemia frequently occurs in patients with other chronic diseases, such as obesity and cardiovascular disease. 95 The increased prevalence of dia betes mellitus in patients with cancer has drawn atten tion to the effects of hyperglycaemia on cancer initiation and progression. 96, 97 The study of glucose metabolism in tumours has been intensively studied since Warburg's observation in the 1950s that tumours face hypoglycaemia in a tumour massdependent manner. 98, 99 These metabolic observa tions prompted a number of groups to look at tumour growth characteristics in hyperglycaemic environ ments using animal models. Severe hypoinsulinaemia was induced in mice by chemical destruction of pan creatic β cells using alloxan, thereby achieving hyper glycaemic conditions in vivo. These mice demonstrated decreased tumour growth owing to the lack of insulin, which functions as a potent mitogenic factor. [100] [101] [102] This observation is also consistent with the current understanding that even though many tumour cells utilize glycolytic mecha nisms, the basic availability of glucose is rarely rate limiting for cancer growth. This experimental limitation in early studies meant that the effects of h yperglycaemia on cancer cells could not be properly investigated.
Our own studies, in which we induced hypergly caemia in mice by prompting apoptosis of pancreatic β cells, convinced us that a 'hyperglycaemic memory effect' in cancer cells contributes to aggressive tumour growth. 103, 104 Hyperglycaemic conditions do induce epi genetic modification of components of some oncogenic pathways, such as the EGFR, HER2 and HER3 signal ling cascades and their corresponding ligands (such as ne uregulin1), thereby stimulating tumour growth even after the cells have been returned to a euglycemic environ ment. 103, 104 Chronic exposure to elevated glucose levels, therefore, induces epigenetic modifications at the level of DNA and chromatin. Identifying hyperglycaemic conditions in patients at the time of diagnosis could help to direct early intervention efforts towards key targets, such as HER3, in the context of breast cancer.
Hyperinsulinaemia and IGF-1 signalling
Obesity is associated with several risk factors for cancer development, specifically hyperinsulinaemia and low serum levels of insulinlike growth factorbinding protein (IGFBP)1.
15,105-109 Overweight individuals also have elevated circulating levels of insulinlike growth factor 1 (IGF1), 110 which could also confer increased suscepti bility to cancer development. Insulin is exclusively pro duced and secreted by pancreatic β cells, whereas IGF1 is mainly produced in the liver. IGF1 and insulin share sequence similarities, 105 and both can activate mitogenic pathways and inhibit cell apoptosis. Obesity can contrib ute to carcinogenesis by activating the IGF1-insulin pathway, which tradition ally stimulates intracellular signalling through mitogenactivated protein kinases (MAPKs) or the PI3K-AKT cascade. 105, [111] [112] [113] In general, insulinreceptormediated signalling regu lates metabolic pathways, whereas proliferation and cell growth are stimulated by IGF1receptormediated signalling, which suggests that the mitogenic effects of insulin might be mediated by IGF1. Insulin increases IGF1 levels through direct regulation of IGF1 transcrip tion. Importantly, in addition to insulin, other factors also regulate IGF bioavailability, such as IGFBPs. Six iso forms of IGFBPs have been identified, of which the most abundant is IGFBP3. Levels of IGFBP3 are regulated by nutrients. 114 Hyperinsulinaemia can reduce levels of IGFBP1, 115 suggesting that insulin might have a criti cal role in obesityaggravated cancer development by r egulating IGFs and IGFBPs.
The insulin receptor and the IGF1 receptor (IGF 1R) are integral to insulin-IGF1 signalling pathways. Insulin and bioavailable IGF1 can crossreact with each other's receptor, and IGF1R and the insulin recep tor can form heterodimers. Insulin receptor-IGF1R hybrids, the insulin receptor, IGF1R and IGF2R phosphorylate insulin receptor substrates, which can then activate MAPKs and ultimately activate the PI3K-AKT oncogenic pathway. In mouse studies, Ig f and Igf1r transgenic mice develop a variety of cancers. [116] [117] [118] [119] [120] Therefore, preventing the obesityinduced activation of the insulin-IGF1 axis could be a viable therapeutic target for cancer.
Sex hormones
Cytochrome P450 aromatase, which is encoded by the CYP19 gene, converts androgens to estrogens 121 and, therefore, has a critical role in determining the balance between the levels of these sex hormones. The ovarian follicle is a major site for producing aromatase in premenopausal women; however, in postmenopausal women aromatase is predominantly produced in adipose tissues and skin. 122 The rate of conversion of androgens to estrogens is elevated in postmenopausal women with obesity, 123, 124 and an increased level of estrogens in these women is associated with an increased risk of breast cancer. 125 Fibroblasts in adipose tissue have long been thought to be critical for aromatase expression, and con sequently for estrogen production. 126, 127 Some researchers have also proposed that cytokines, prostaglandins and hormones regulate aromatase gene expression in obesity; for example, levels of prostaglandin E 2 are elevated in obesity and promote aromatase expression in breast adipose tissues. 128 Obesity is associated with increased activity and expression of aromatase in certain cancers. Moreover, obesity is a chronic inflammatory state in which circu lating levels of proinflammatory cytokines such as TNF and IL6 are elevated, and TNF can induce aromatase expression in human adipose stromal cells. 129 Blocking aromatase to inhibit estrogen production is an effective initial therapeutic strategy for estrogen receptorpositive breast cancers until drug resistance develops. Wholegenome analysis of breast cancer samples identified 18 mutations that were associated with differential survival after treatment with an aroma tase inhibitor; 130 however, currently little is known about the mechanisms and factors that contribute to responses to aromatase inhibitor therapy. Results from a study that assessed chromatinbinding on a genomewide scale suggested that the binding pattern of estrogen recep tor α to target promoters and epigenetic modifications of H3K27me3 regulate drug resistance to aromatase i nhibitors in breast cancer. 131 
Prevention and treatment

Metformin
In the past decade, a series of publications reported that patients with T2DM who were treated with the oral bigu anide metformin had a lower incidence of cancer than did their counterparts taking other medications for dia betes mellitus, including insulin and sulfonylureas. 132, 133 A number of studies have since attempted to determine the molecular mechanisms mediating this reduction in cancer incidence.
Metformin requires activation of AMPK to elicit its antidiabetic effects. 134 AMPKdependent inhibition of insulinstimulated growth has been demonstrated in several breast cancer cell lines. 135 Metformininduced AMPK activation in these cell lines led to growth inhi bition, and siRNAmediated knockdown of AMPK was sufficient to restore the proliferative response to insulin stimulation. Metformin blocked protein translation via inhibition of mTOR, and this effect was specific ally dependent on the serine-threonineprotein kinase STK11 (LKB1). 136 Emerging data have demonstrated that metformin can selectively kill CSCs, as determined by decreased numbers of CD44 high CD24 low cells. 137 This effect was especially strong following combination therapy with doxorubicin, and this treatment regime caused prolonged remission in a xenograft model. Metformin is highly active against cancer growth, and clinical trials are currently being conducted for a number of different malignancies.
Thiazolidinediones
The thiazolidinediones (a class of peroxisome prolifera toractivated receptor γ agonists) have growthinhibitory effects on transformed cells. 138 When these com pounds were tested in combination treatment regimes, an unexpectedly potent synergy was observed between the platinum based agent cisplatin and thiazolidine diones. 139, 140 Initial analysis revealed that treatment with rosiglitazone reduced metallothionine expression, which was at least partially responsible for the increased effi cacy of cisplatin. 140 However, our group's data present a different view of how thiazolidinediones might sensitize tumours to cisplatinbased chemotherapy. 48 Our analysis of the tumour micro environment showed that treatment with cisplatin robustly increased the production of colla gen α3(VI) chain, and that thiazolidinediones very effec tively suppressed this alteration. In the MMTVPyMT breast cancer model, tumours in collagen α3(VΙ) knock out mice are highly sensitized to cisplatin, and reconsti tution with endotrophin restored tumour resistance to cisplatin. Inhibition of endotrophin with a monoclonal antibody also enhanced tumour sensitivity to cisplatin, suggesting that targeting this pathway might provide new possibilities for treatment in patients with tumour r esistance to platinumbased therapies. 48 Exercise For decades, debates have been waged over the effects of exercise on tumour initiation and progression. Despite heated controversy, this aspect of cancer physiology has proven particularly difficult to study, owing to the lack of longterm controlled trials and variability between exer cise regimes. Taking these factors into consideration, a large comprehensive metaanalysis reported reasonable benefits, in terms of quality of life, cardiorespiratory fitness and overall patient wellbeing, in response to exer cise therapy during breast cancer treatment. 141 However, few studies have positively correlated survival in breast cancer patients with exercise regimes. An 18 year longitu dinal study of 2,900 participants linked increased aerobic exercise following breast cancer diagnosis with improved survival; however, although trends were a pparent, no data in the study reached statistical significance. 142 Many studies have used carcinogeninduced tumours in rodent models to test the potential of exercise to protect against cancer initiation and progression. A major confounding variable in these experiments is that the carcino gen used in most breast cancer studies, 2,7 dimethylbenzanthracene, is a procarcinogen that is converted to its active form in the liver, a metabolic process that might possibly be affected by exercise. Despite this concern, a comprehensive review on the subject reported a positive benefit from exercise on reducing tumour development in both 2,7 dimethylbenzanthracene and NmethylNnitrosoureainduced mammary tumours. 143 Whilst exercise slowed the progression of NmethylN nitrosoureainduced mammary cancers in some studies, it potentiated 2,7dimethylbenzanthraceneinduced carcino genesis in other studies. 144, 145 Although these results are intriguing they are most likely not directly applicable to understanding human tumour initiation and progression. The limited available evidence does suggest that exercise may have beneficial effects, such as an improved prognosis, in patients with cancer. As indivi dual responses to exercise are difficult to predict, and alterations in whole body metabolism, including changes in levels of circulating adipokines, may be different, more research is needed to identify the patient cohorts that are most likely to benefit from exercise.
Weight loss
The effect of weight loss on tumour initiation and pro gression is an important issue that offers a means for testing the reversibility of some mechanisms triggered by obesity. In a study of 2,437 women who underwent surgical resection of earlystage breast cancer, partici pants who were assigned to an intervention group with decreased dietary fat intake experienced concomitant weight loss and an improved rate of relapsefree survival compared with women in the control group; however, the mechanisms underlying this effect are unclear. 146 As previously discussed, inflammation in adipose tissues is regarded as a critical mediator of both obesity and cancer. Creactive protein (CRP) levels, a serum marker of inflammation, are increased in individuals who are overweight or have obesity 147 and decline with weight loss. 113, 148 In a randomized controlled trial in postmeno pausal women, weight loss achieved by caloric restric tion was associated with a reduction in levels of several inflammatory markers, such as serum amyloid A, CRP and IL6. Exercise combined with caloric restriction did not result in differences in levels of inflamma tory markers when compared with caloric restriction alone. 149 Although these findings are promising, whether the reductions in the levels of inflammatory markers were caused by caloric restriction itself, or by its weight lossassociated metabolic benefits, is currently not clear. Furthermore, hypoxia increases levels of vascular endo thelial growth factor (VEGF) in adipocytes and has a crucial role in tumour angiogenesis. Elevated BMI is also associated with increased levels of VEGF, 150 which are also associated with poor outcomes in patients with obesity. 146 Despite accumulating evidence for an anti cancer role for both weight loss and caloric restriction, longterm studies with larger cohorts and better controls than have so far been conducted are still needed.
Conclusions and future directions
Patients with obesity are widely accepted to be at an increased risk of initiation, growth and progression of certain cancers; however, the molecular mechanisms that underlie these associations remain elusive. A model in which cancer cells reprogram adipocytes into CAAs to support tumour growth is emerging. Subsequent to being reprogrammed, CAAs provide a tumour permissive microenvironment by releasing inflammatory, fibro tic and angiogenic factors, in addition to various lipids and other metabolites that promote tumour growth and metastasis (Figure 2 ).
In the context of this model, it is not surprising that targeting adipose tissues with antiobesity and/or anti diabetic agents, such as metformin and thiazolidi nediones, might be a promising option to treat patients with cancer who are overweight or have obesity. Under standing the heterotypic interactions between adipo cytes and cancer cells, which occur through paracrine signals, could lead to the identification of further novel targets for cancer therapies. Lifestyle interventions, such as exercise and weight loss, might also be considered as basic public health strategies for cancer prevention and treatment. The effects of exercise and/or weight loss on cancer mortality and recurrence are not yet clear, but this area is intuitively relevant for further studies. A provocative question is whether reducing obesity is the only viable therapeutic approach to effectively decrease risk and improve outcomes for patients with cancer who are overweight or have obesity. Developing a mechanistic understanding of the contribution of dysfunctional adipose tissue to cancer progression will certainly reveal direct molecular targets for treating cancer in patients with high BMIs. In an age of indivi dualized cancer therapy, an unmet need clearly remains for develop ment of targeted therapeutic approaches for patients with obesity and cancer.
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